These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38929126)

  • 41. Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view.
    Quiroga B; de Santos A; Sapiencia D; Saharaui Y; Álvarez-Chiva V
    Nefrologia (Engl Ed); 2019; 39(6):646-652. PubMed ID: 31027894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oxidative Stress in the Pathogenesis and Evolution of Chronic Kidney Disease: Untangling Ariadne's Thread.
    Duni A; Liakopoulos V; Roumeliotis S; Peschos D; Dounousi E
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antioxidants for chronic kidney disease.
    Jun M; Venkataraman V; Razavian M; Cooper B; Zoungas S; Ninomiya T; Webster AC; Perkovic V
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008176. PubMed ID: 23076940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Chronic renal disease, inflammation and atherosclerosis: new concepts about an old problem].
    Dummer CD; Thomé FS; Veronese FV
    Rev Assoc Med Bras (1992); 2007; 53(5):446-50. PubMed ID: 17952355
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gut Microbiota and Cardiovascular Uremic Toxicities.
    Velasquez MT; Centron P; Barrows I; Dwivedi R; Raj DS
    Toxins (Basel); 2018 Jul; 10(7):. PubMed ID: 29997362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
    Cooper TE; Khalid R; Chan S; Craig JC; Hawley CM; Howell M; Johnson DW; Jaure A; Teixeira-Pinto A; Wong G
    Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013631. PubMed ID: 37870148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vascular incompetence in dialysis patients--protein-bound uremic toxins and endothelial dysfunction.
    Jourde-Chiche N; Dou L; Cerini C; Dignat-George F; Brunet P
    Semin Dial; 2011; 24(3):327-37. PubMed ID: 21682773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease.
    Addi T; Dou L; Burtey S
    Toxins (Basel); 2018 Oct; 10(10):. PubMed ID: 30322010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiorenal benefits of finerenone: protecting kidney and heart.
    González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
    Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies.
    Hamed SA
    Expert Rev Clin Pharmacol; 2019 Jan; 12(1):61-90. PubMed ID: 30501441
    [No Abstract]   [Full Text] [Related]  

  • 52. Uremic toxins, oxidative stress, and renal fibrosis: an interwined complex.
    Chao CT; Chiang CK
    J Ren Nutr; 2015 Mar; 25(2):155-9. PubMed ID: 25511523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Cognitive impairment and the blood-brain barrier in chronic kidney disease: role of the uremic toxins].
    Bobot M
    Nephrol Ther; 2023 Dec; 19(7):607-615. PubMed ID: 38059844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hippuric Acid Promotes Renal Fibrosis by Disrupting Redox Homeostasis via Facilitation of NRF2-KEAP1-CUL3 Interactions in Chronic Kidney Disease.
    Sun B; Wang X; Liu X; Wang L; Ren F; Wang X; Leng X
    Antioxidants (Basel); 2020 Aug; 9(9):. PubMed ID: 32854194
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease.
    Górriz JL; González-Juanatey JR; Facila L; Soler MJ; Valle A; Ortiz A
    Nefrologia (Engl Ed); 2023; 43(4):386-398. PubMed ID: 37813743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease.
    Kaminski TW; Pawlak K; Karbowska M; Znorko B; Mor AL; Mysliwiec M; Pawlak D
    Int Urol Nephrol; 2019 Mar; 51(3):491-502. PubMed ID: 30617956
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oxidative stress in chronic kidney disease.
    Modaresi A; Nafar M; Sahraei Z
    Iran J Kidney Dis; 2015 May; 9(3):165-79. PubMed ID: 25957419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β
    Yamamoto S
    Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The AKI-to-CKD Transition: The Role of Uremic Toxins.
    André C; Bodeau S; Kamel S; Bennis Y; Caillard P
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
    Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.